Literature DB >> 19548917

Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease.

Luca Arcaini1, Marco Lucioni, Emanuela Boveri, Marco Paulli.   

Abstract

Nodal marginal zone lymphoma (NMZL) is a defined, separate clinicopathological entity. NMZL is a B-cell neoplasm originated in the lymph node, whose histology resembles the nodal infiltration by mucosa-associated lymphoid tissue- or splenic-type marginal zone lymphoma, in the absence of clinical evidence of extranodal or spleen disease. The lack of characteristic phenotypic or molecular diagnostic findings is still hampering the reproducibility of this diagnosis. Herein, we review the main morphological and immunophenotypical markers, discussing the differential with other overlapping entities. We also summarize the clinical features and outcome of this rare lymphoma and we discuss the possible association with hepatitis C virus infection.

Entities:  

Mesh:

Year:  2009        PMID: 19548917     DOI: 10.1111/j.1600-0609.2009.01301.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

Review 1.  Rare pediatric non-hodgkin lymphoma.

Authors:  Bhuvana A Setty; Amanda M Termuhlen
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

Review 2.  Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.

Authors:  Nathan M Denlinger; Narendranath Epperla; Basem M William
Journal:  Cancer Manag Res       Date:  2018-03-27       Impact factor: 3.989

3.  IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications.

Authors:  Massimo Granai; Teresa Amato; Arianna Di Napoli; Raffaella Santi; Federica Vergoni; Gioia Di Stefano; Virginia Mancini; Sofya Kovalchuk; Emanuele Cencini; Alberto Giulio Carta; Sara Aversa; Marita Ziepert; Gabriele Cevenini; Stefano Lazzi; Lorenzo Leoncini; Cristiana Bellan
Journal:  Virchows Arch       Date:  2019-12-04       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.